30-day clinical outcome
| Total (n=1007) | Non-HPR (n=664, 66%) | Individualised (n=343, 34%) | Adjusted HR (95% CI) p Value | Crude HR (95% CI) p Value | |
|---|---|---|---|---|---|
| MACE (cardiovascular death, myocardial infarction, stent thrombosis) | 18 (1.8%) | 9 (1.4%) | 9 (2.6%) | 0.67 (0.23 to 2.03) 0.5 | 0.51 (0.20 to 1.30) 0.16 |
| Cardiovascular death | 18 (1.8%) | 9 (1.4%) | 9 (2.6%) | ||
| Non-shock | 8 (0.8%) | 4 (0.6%) | 4 (1.2%) | ||
| Cardiogenic shock (n=shock patients; % of shock) | 10 (26; 38%) | 5 (8; 62%) | 5 (18; 28%) | ||
| Myocardial infarction Stent thrombosis | 1 (0.09%) | 1 (0.15%) | 0 (0%) | ||
| Definite and probable | 3 (0.29%) | 3 (0.45%) | 0 (0%) | ||
| Definite | 1 (0.09%) | 1 (0.15%) | 0 (0%) | ||
| Probable | 2 (0.19%) | 2 (0.3%) | 0 (0%) | ||
| Bleeding | |||||
| TIMI major and minor | 26 (2.6%) | 17 (2.6%) | 9 (2.6%) | 0.78 (0.33 to 1.85) 0.574 | 0.96 (0.42 to 2.20) 0.914 |
| TIMI major | 10 (1.0%) | 6 (0.9%) | 4 (1.2%) | ||
| TIMI minor | 16 (1.6%) | 11 (1.7%) | 5 (1.5%) | ||
| Type | |||||
| Instrumented | 14 (1.4%) | 10 (1.5%) | 4 (1.2%) | ||
| Spontaneous | 12 (1.2%) | 7 (1.1%) | 5 (1.5%) |
MACE, major adverse cardiac event; TIMI, thrombolysis in myocardial infarction.